Ketamine Treatment Side Effects: Labs, Monitoring, and Next Steps

Why Ketamine Therapy Causes Side Effects

Ketamine blocks the N-methyl-D-aspartate (NMDA) receptor, which triggers a rapid glutamate surge and downstream synaptic remodeling. That same receptor blockade also disrupts normal sensory processing, autonomic regulation, and smooth-muscle tone in organs like the bladder. Side effects are dose-dependent and route-dependent. A low-dose IV infusion (0.5 mg/kg over 40 minutes) carries a different risk profile than repeated high-dose oral or intranasal use.

The FDA approved intranasal esketamine (Spravato) in 2019 specifically for treatment-resistant depression (TRD), and the prescribing label lists dissociation, sedation, elevated blood pressure, nausea, and vertigo as the most frequent adverse events [1]. In SUSTAIN-1, the phase 3 maintenance trial (N=297), the overall discontinuation rate due to adverse events was 7% in the esketamine group versus 5% in placebo [2]. Short-term side effects usually resolve within two hours. Long-term organ toxicity, specifically to the liver and urinary tract, depends on cumulative exposure and requires scheduled lab surveillance. Genetic polymorphisms in hepatic CYP2B6 and CYP3A4 enzymes also influence how quickly a patient metabolizes ketamine, which partly explains why some individuals are more sensitive than others at the same dose [3].

Acute Side Effects and How Often They Happen

Dissociation is the most recognizable acute effect. In pooled data from the esketamine trials for TRD, 61% of patients reported dissociative symptoms during at least one dosing session, though fewer than 1% discontinued treatment because of it [4]. The experience typically peaks at 40 minutes and fades by 90 minutes.

Blood pressure elevation is the acute effect that demands the most clinical vigilance. Systolic increases of 7 to 9 mmHg (mean) were observed across esketamine trials, but individual spikes can exceed 40 mmHg systolic [1]. The FDA REMS program for Spravato requires in-clinic blood pressure checks at 40 minutes and again before discharge. Patients with uncontrolled hypertension, aneurysmal vascular disease, or a history of intracerebral hemorrhage are excluded from esketamine prescribing per the label.

Nausea affects approximately 27 to 29% of esketamine patients compared to 9% receiving placebo, based on pooled phase 3 data [4]. Pretreatment with ondansetron 4 mg orally, given 30 minutes before the session, reduces emetic episodes in clinical practice. Headache (20%), dizziness (23%), and somnolence (23%) round out the top five acute adverse events. These percentages come from the Janssen-submitted safety database reviewed by the FDA during the 2019 approval [1].

A simple rule: if any acute side effect does not begin resolving within two hours, the supervising clinician should extend monitoring and document the event for dose-adjustment decisions at the next visit.

Liver and Hepatic Monitoring

Repeated ketamine exposure can raise hepatic transaminases. A 2013 case series published in the journal Liver International documented cholestatic liver injury in three patients receiving repeated ketamine infusions for chronic pain, with peak ALT values ranging from 300 to over 1,000 U/L [5]. The American Association for the Study of Liver Diseases (AASLD) notes that drug-induced liver injury (DILI) should be suspected when ALT exceeds 5x the upper limit of normal or when ALT exceeds 3x ULN alongside a bilirubin rise above 2x ULN (Hy's Law threshold) [6].

Baseline labs should include a comprehensive metabolic panel (CMP) with ALT, AST, alkaline phosphatase, and total bilirubin. Recheck LFTs at 4 weeks after initiation, then every 3 months during ongoing therapy. If ALT climbs above 3x ULN, the prescribing clinician should hold the next ketamine dose and repeat labs in 1 to 2 weeks. Persistent elevation warrants hepatology referral and treatment discontinuation.

A 2022 retrospective chart review of 220 patients receiving IV ketamine for TRD at a U.S. academic center found that 4.1% developed transaminase elevations above 2x ULN, and all cases resolved after dose reduction or discontinuation [7]. The low rate is reassuring for standard psychiatric dosing protocols (0.5 mg/kg), but patients receiving higher analgesic doses or more frequent infusion schedules face greater hepatic exposure.

Bladder and Urinary Tract Damage

Ketamine cystitis was first described in recreational users, but clinicians now recognize it in therapeutic settings too. The mechanism involves direct toxicity of ketamine and its metabolite norketamine to the urothelium, causing mucosal inflammation, reduced bladder capacity, and fibrosis over time [8]. A systematic review in BJU International (2014) reported lower urinary tract symptoms in 20 to 30% of chronic recreational ketamine users, with severity correlating to cumulative lifetime dose [8].

At therapeutic doses for depression, bladder toxicity is far less common. The SUSTAIN and TRANSFORM trials did not report clinically significant urinary tract adverse events over their observation windows [2]. The risk increases, though, with off-label chronic pain protocols that use higher or more frequent doses over months to years.

Baseline and periodic urinalysis (every 3 to 6 months) screens for microscopic hematuria and pyuria. Any patient reporting urinary frequency, urgency, suprapubic pain, or gross hematuria during ketamine therapy should undergo urology workup including cystoscopy and bladder-capacity measurement. Early detection and dose cessation can prevent irreversible fibrosis. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) provides patient resources on interstitial cystitis, which shares symptom overlap with ketamine cystitis and should be considered in the differential [9].

Cardiovascular Monitoring Beyond Blood Pressure

Ketamine is a sympathomimetic. It raises heart rate, blood pressure, and cardiac output through central and peripheral norepinephrine release. For healthy adults, these transient changes are clinically benign. For patients with coronary artery disease, heart failure, or arrhythmia history, the risk calculation shifts.

The American Heart Association scientific statement on psychotropic drug cardiovascular effects (2023) notes that ketamine's sympathomimetic properties require pre-treatment cardiac risk stratification in patients with known cardiovascular disease [10]. A resting 12-lead ECG before the first infusion is reasonable in patients over age 50 or those with cardiac risk factors. Continuous pulse oximetry and automated blood pressure cycling every 15 minutes during infusion are standard practice in most ketamine clinics.

Post-session tachycardia lasting beyond 2 hours, new-onset chest pain, or sustained systolic blood pressure above 180 mmHg should trigger immediate clinical evaluation and possible emergency referral. These events are rare at standard psychiatric doses but not zero-probability.

Neuropsychiatric and Cognitive Effects

Short-term cognitive disruption during and immediately after ketamine dosing is expected. Attention, working memory, and verbal fluency scores dip during acute infusion and return to baseline within 2 to 4 hours in most studies [11]. A 2020 systematic review in the Journal of Affective Disorders (14 studies, pooled N=648) found no persistent neurocognitive deficits after repeated subanesthetic ketamine infusions for depression over 2 to 12 weeks [11].

Long-term cognitive safety data remain limited. The longest controlled follow-up for esketamine (SUSTAIN-2, open-label) extended to approximately one year and did not detect progressive cognitive decline on the Cogstate battery [12]. Clinicians should still monitor for subjective memory complaints at each visit, and any patient reporting progressive difficulty with recall or executive function should undergo formal neuropsychological testing.

Psychotomimetic symptoms, including perceptual disturbances and paranoid ideation, occur during acute dosing in a small percentage of patients. They are more common at higher doses and in patients with a personal or family history of psychotic disorders. Active psychosis remains a contraindication to ketamine-based therapy per the Spravato REMS [1].

"Patients with a history of psychosis should not receive esketamine. The dissociative and perceptual effects, while transient in most patients, can destabilize individuals with underlying psychotic vulnerability," notes the FDA Risk Evaluation and Mitigation Strategy (REMS) document for Spravato [1].

The Complete Baseline Lab Panel

Before the first ketamine session, the following labs establish an organ-function baseline:

• Complete blood count (CBC): screens for anemia and infection markers
• Comprehensive metabolic panel (CMP): includes electrolytes, BUN, creatinine, glucose, ALT, AST, alkaline phosphatase, total bilirubin, and albumin
• Urinalysis with microscopy: baseline for hematuria, proteinuria, and urothelial cell abnormalities
• Thyroid-stimulating hormone (TSH): rules out thyroid dysfunction as a contributor to depressive symptoms and identifies a condition that may alter ketamine metabolism
• Lipid panel: relevant if cardiovascular risk stratification is needed
• Urine drug screen: identifies concurrent substance use that may interact with ketamine or alter risk
• Pregnancy test (if applicable): ketamine is not recommended in pregnancy due to insufficient safety data
• 12-lead ECG (conditional): indicated for patients over 50, those with known cardiac disease, or anyone on QT-prolonging medications

The APA Practice Guidelines for the treatment of depression do not yet include a ketamine-specific lab protocol, but the American Psychiatric Association's 2023 consensus statement on ketamine and esketamine use in mood disorders recommends pre-treatment medical evaluation including vital signs, psychiatric assessment, and relevant blood work [13].

Ongoing Monitoring Schedule

Monitoring does not stop after the baseline panel. A practical schedule for patients on maintenance ketamine or esketamine therapy:

Every session: blood pressure (pre-dose, 40 minutes, and pre-discharge), pulse oximetry, dissociation assessment (Clinician-Administered Dissociative States Scale or equivalent), and subjective side-effect check.

Monthly for the first 3 months: LFTs (ALT, AST, ALP, bilirubin), blood pressure log review, mood outcome tracking (PHQ-9 or MADRS), and side-effect diary review.

Every 3 to 6 months thereafter: CMP, urinalysis, cognitive screening (self-report plus clinician assessment), and reassessment of treatment goals. If a patient has been on therapy for over 12 months, annual cystoscopy may be considered if urinary symptoms develop.

"We recommend that all patients receiving repeated ketamine treatments undergo periodic hepatic and renal function testing, with urinalysis to monitor for early signs of ketamine-associated uropathy," states a 2021 consensus guideline published in the American Journal of Psychiatry [14].

Next Steps If Side Effects Appear

The clinical response depends on which side effect emerges and its severity.

Persistent nausea: Add or adjust anti-emetic prophylaxis (ondansetron 4 to 8 mg, or granisetron 1 mg). If nausea persists despite prophylaxis, reduce the ketamine dose by 20 to 25% at the next session. Switching from intranasal to IV route (or vice versa) sometimes changes the nausea profile.

Blood pressure elevation above 180/110 mmHg: Withhold the next dose. Start or optimize antihypertensive therapy. Re-attempt ketamine only after two consecutive pre-session blood pressure readings fall below 140/90 mmHg. Consider cardiology consultation for refractory hypertension.

Transaminase elevation above 3x ULN: Hold ketamine. Repeat LFTs in 1 to 2 weeks. If ALT does not trend down, refer to hepatology and discontinue ketamine therapy. If enzymes normalize, reintroduce at a lower dose with biweekly LFT monitoring for the first 8 weeks.

Urinary symptoms (frequency, urgency, pain, hematuria): Obtain urinalysis and urine cytology. Refer to urology for cystoscopy if hematuria is present or symptoms persist beyond 2 weeks after ketamine discontinuation. Pentosan polysulfate sodium (Elmiron) and bladder instillations with hyaluronic acid have been used for ketamine cystitis, though evidence is limited to case series [8].

Worsening depression or suicidal ideation between sessions: This requires immediate psychiatric reassessment. Ketamine's antidepressant effect can wane between doses, and some patients experience a "crash" phenomenon. Adjusting session frequency (from biweekly to weekly) or adding a conventional antidepressant may stabilize mood between infusions.

Dissociation that the patient finds intolerable: Reduce the dose by 15 to 25%. Pre-treatment with a low-dose benzodiazepine (e.g., lorazepam 0.5 mg) can blunt dissociation, but it may also reduce antidepressant efficacy based on retrospective data from a 2017 Columbia University study (N=42) [15].

When to Stop Ketamine Therapy

Discontinuation is indicated when organ toxicity is confirmed (persistent LFT elevation, biopsy-proven cystitis), when cardiovascular risk becomes unmanageable, when the patient develops signs of ketamine use disorder (craving, dose escalation, use outside clinical settings), or when the treatment fails to produce meaningful mood improvement after an adequate trial (typically 6 to 8 sessions at therapeutic doses).

The decision to stop is not always permanent. Some patients pause, address the complicating factor, and resume at a lower dose with tighter monitoring. Others transition to alternative treatments: transcranial magnetic stimulation (TMS), electroconvulsive therapy (ECT), or augmentation strategies with lithium or atypical antipsychotics.

Any patient discontinuing esketamine after long-term use should have a follow-up psychiatric visit within 1 to 2 weeks to monitor for depressive relapse, given that SUSTAIN-1 showed relapse rates of 26.7% in patients switched from esketamine to placebo over a median of 2 months [2].